Sibutramine: current status as an anti-obesity drug and its future perspectives

Bibliography

• World Health Organization. Available from: www.who.int/mediacentre/factsheets/fs311/en/
   Google Scholar
• Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999 – 2004. JAMA 2006;295(13):1549-55
   PubMed Web of Science ®Google Scholar
• Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20(4):537-44
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344(18):1343-50
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393-403
   PubMed Web of Science ®Google Scholar
• Haslam DW, James WP. Obesity. Lancet 2005;366(9492):1197-209
   PubMed Web of Science ®Google Scholar
• Avenell A, Brown TJ, McGee MA, et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet 2004;17(4):293-316
   PubMed Web of Science ®Google Scholar
• Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007;369(9555):71-7
   PubMed Web of Science ®Google Scholar
• Brown SA, Upchurch S, Anding R, et al. Promoting weight loss in type II diabetes. Diabetes Care 1996;19(6):613-24
   PubMed Web of Science ®Google Scholar
• Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2003;(4):CD004094
   PubMedGoogle Scholar
• Khan MA, St Peter JV, Breen GA, et al. Diabetes disease stage predicts weight loss outcomes with long-term appetite suppressants. Obes Res 2000;8(1):43-8
   PubMedGoogle Scholar
• Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353(20):2111-20
   PubMed Web of Science ®Google Scholar
• Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity. JAMA 1996;276(23):1907-15
   PubMed Web of Science ®Google Scholar
• Aylwin S, Al-Zaman Y. Emerging concepts in the medical and surgical treatment of obesity. Front Horm Res 2008;36:229-59
   PubMed Web of Science ®Google Scholar
• Cannistra LB, Davis SM, Bauman AG. Valvular heart disease associated with dexfenfluramine. N Engl J Med 1997;337(9):636
   PubMed Web of Science ®Google Scholar
• McCann UD, Seiden LS, Rubin LJ, Ricaurte GA. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence. JAMA 1997;278(8):666-72
   PubMed Web of Science ®Google Scholar
• Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000;343(25):1826-32
   PubMed Web of Science ®Google Scholar
• The global pharmaceutical market: a detailed look at 2002. London: Intercontinental Medical Statistics Health; 2003
   Google Scholar
• Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005;8(5):585-9
   PubMed Web of Science ®Google Scholar
• McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998;56(6):1093-124
   PubMed Web of Science ®Google Scholar
• Cheetham SC, Heal DJ. Evidence that RU 24969-induced locomotor activity in C57/B1/6 mice is specifically mediated by the 5-HT1B receptor. Br J Pharmacol 1993;110(4):1621-9
   PubMed Web of Science ®Google Scholar
• Cheetham SC, Viggers JA, Butler SA, et al. [3H]nisoxetine – a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments. Neuropharmacology 1996;35(1):63-70
   PubMed Web of Science ®Google Scholar
• Cheetham SC, Viggers JA, Slater NA, Heal DJ. Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine. Neuropharmacology 2000;39(11):2028-35
   PubMed Web of Science ®Google Scholar
• Jackson HC, Needham AM, Hutchins LJ, et al. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br J Pharmacol 1997;121(8):1758-62
   PubMed Web of Science ®Google Scholar
• Heal DJ, Aspley S, Prow MR, et al. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 1998;22(Suppl 1):S18-28; discussion S29
   PubMed Web of Science ®Google Scholar
• Heal DJ, Cheetham SC, Prow MR, et al. A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents. Br J Pharmacol 1998;125(2):301-8
   PubMed Web of Science ®Google Scholar
• Heal DJ, Frankland AT, Gosden J, et al. A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine. Psychopharmacology (Berl) 1992;107(2-3):303-9
   PubMed Web of Science ®Google Scholar
• Rolls BJ, Shide DJ, Thorwart ML, Ulbrecht JS. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 1998;6(1):1-11
   PubMedGoogle Scholar
• Jackson HC, Bearham MC, Hutchins LJ, et al. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 1997;121(8):1613-8
   PubMed Web of Science ®Google Scholar
• Hansen DL, Toubro S, Stock MJ, et al. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 1999;23(10):1016-24
   PubMed Web of Science ®Google Scholar
• Grignaschi G, Fanelli E, Scagnol I, Samanin R. Studies on the role of serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats. Br J Pharmacol 1999;127(5):1190-4
   PubMed Web of Science ®Google Scholar
• Connoley IP, Liu YL, Frost I, et al. Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol 1999;126(6):1487-95
   PubMed Web of Science ®Google Scholar
• Liu YL, Heal DJ, Stock MJ. Mechanism of the thermogenic effect of Metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine. Int J Obes Relat Metab Disord 2002;26(9):1245-53
   PubMed Web of Science ®Google Scholar
• Astrup A, Hansen DL, Lundsgaard C, Toubro S. Sibutramine and energy balance. Int J Obes Relat Metab Disord 1998;22(Suppl 1):S30-5; discussion S36-7, S42
   Google Scholar
• Hansen DL, Toubro S, Stock MJ, et al. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998;68(6):1180-6
   PubMed Web of Science ®Google Scholar
• Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord 1997;21(Suppl 1):S25-9
   Web of Science ®Google Scholar
• Sarac F, Pehlivan M, Celebi G, et al. Effects of sibutramine on thermogenesis in obese patients assessed via immersion calorimetry. Adv Ther 2006;23(6):1016-29
   PubMed Web of Science ®Google Scholar
• Danforth E Jr. Sibutramine and thermogenesis in humans. Int J Obes Relat Metab Disord 1999;23(10):1007-8
   PubMed Web of Science ®Google Scholar
• Nisoli E, Briscini L, Giordano A, et al. Tumor necrosis factor alpha mediates apoptosis of brown adipocytes and defective brown adipocyte function in obesity. Proc Natl Acad Sci USA 2000; 97(14):8033-8
   PubMed Web of Science ®Google Scholar
• Seagle HM, Bessesen DH, Hill JO. Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes Res 1998;6(2):115-21
   PubMedGoogle Scholar
• Starling RD, Liu X, Sullivan DH. Influence of sibutramine on energy expenditure in African American women. Obes Res 2001;9(4):251-6
   PubMedGoogle Scholar
• Rotstein A, Inbar O, Vaisman N. The effect of sibutramine intake on resting and exercise physiological responses. Ann Nutr Metab 2008;52(1):17-23
   PubMed Web of Science ®Google Scholar
• Walsh KM, Leen E, Lean ME. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int J Obes Relat Metab Disord 1999;23(10):1009-15
   PubMed Web of Science ®Google Scholar
• Halford JC, Wanninayake SC, Blundell JE. Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 1998;61(2):159-68
   PubMed Web of Science ®Google Scholar
• Hansen D, Astrup A, Toubro S, et al.; Goulder For The SSGM. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance. Int J Obes Relat Metab Disord 2001;25(4):496-501
   PubMed Web of Science ®Google Scholar
• Elfhag K, Rossner S, Carlsson AM, Barkeling B. Sibutramine treatment in obesity: predictors of weight loss including rorschach personality data. Obes Res 2003;11(11):1391-9
   PubMedGoogle Scholar
• Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res 1999;7(2):189-98
   PubMedGoogle Scholar
• Apfelbaum M, Vague P, Ziegler O, et al. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106(2):179-84
   PubMed Web of Science ®Google Scholar
• Mathus-Vliegen EM. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study. Eur J Clin Nutr 2005;59(Suppl 1):S31-8; discussion S39
   Google Scholar
• Paisey RB, Frost J, Harvey P, et al. Five year results of a prospective very low calorie diet or conventional weight loss programme in type 2 diabetes. J Hum Nutr Diet 2002;15(2):121-7
   PubMed Web of Science ®Google Scholar
• Early JL, Apovian CM, Aronne LJ, et al. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients. Obesity (Silver Spring) 2007;15(6):1464-72
   PubMed Web of Science ®Google Scholar
• Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes Relat Metab Disord 2000;24(2):144-50
   PubMed Web of Science ®Google Scholar
• Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. Int J Obes Relat Metab Disord 2001;25(5):741-7
   PubMed Web of Science ®Google Scholar
• James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356(9248):2119-25
   PubMed Web of Science ®Google Scholar
• Tambascia MA, Geloneze B, Repetto EM, et al. Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. Diabetes Obes Metab 2003;5(5):338-44
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Aggressive weight reduction treatment in the management of type 2 diabetes. Diabetes Metab 1998;24(2):116-23
   PubMed Web of Science ®Google Scholar
• Hung YJ, Chen YC, Pei D, et al. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with type 2 diabetes. Diabet Med 2005;22(8):1024-30
   PubMed Web of Science ®Google Scholar
• McLaughlin T, Abbasi F, Lamendola C, et al. Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity. Metabolism 2001;50(7):819-24
   PubMed Web of Science ®Google Scholar
• Tankova T, Dakovska G, Lazarova M, et al. Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. Acta Diabetol 2004;41(4):146-53
   PubMed Web of Science ®Google Scholar
• Redmon JB, Raatz SK, Reck KP, et al. One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial. Diabetes Care 2003;26(9):2505-11
   PubMed Web of Science ®Google Scholar
• Finer N, Bloom SR, Frost GS, et al. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000;2(2):105-12
   PubMed Web of Science ®Google Scholar
• McNulty SJ, Ur E, Williams G. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003;26(1):125-31
   PubMed Web of Science ®Google Scholar
• Serrano-Rios M, Melchionda N, Moreno-Carretero E. Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med 2002;19(2):119-24
   PubMed Web of Science ®Google Scholar
• Sanchez-Reyes L, Fanghanel G, Yamamoto J, et al. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2004;26(9):1427-35
   PubMed Web of Science ®Google Scholar
• Wang TF, Pei D, Li JC, et al. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. Int J Clin Pract 2005;59(7):746-50
   PubMed Web of Science ®Google Scholar
• Fujioka K, Seaton TB, Rowe E, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000;2(3):175-87
   PubMed Web of Science ®Google Scholar
• Dujovne CA, Zavoral JH, Rowe E, Mendel CM. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am Heart J 2001;142(3):489-97
   PubMed Web of Science ®Google Scholar
• Faria AN, Ribeiro Filho FF, Kohlmann NE, et al. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. Diabetes Obes Metab 2005;7(3):246-53
   PubMed Web of Science ®Google Scholar
• Hazenberg BP. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 2000;94(3):152-8
   PubMed Web of Science ®Google Scholar
• Sharma AM. Sibutramine in overweight/obese hypertensive patients. Int J Obes Relat Metab Disord 2001;25(Suppl 4):S20-3
   Google Scholar
• Ersoz HO, Ukinc K, Baykan M, et al. Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study. Int J Obes Relat Metab Disord 2004;28(3):378-83
   PubMed Web of Science ®Google Scholar
• Sramek JJ, Leibowitz MT, Weinstein SP, et al. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. J Hum Hypertens 2002;16(1):13-9
   PubMed Web of Science ®Google Scholar
• McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000;160(14):2185-91
   PubMed Web of Science ®Google Scholar
• McMahon FG, Weinstein SP, Rowe E, et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002;16(1):5-11
   PubMed Web of Science ®Google Scholar
• Scholze J, Grimm E, Herrmann D, et al. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation 2007;115(15):1991-8
   PubMed Web of Science ®Google Scholar
• Gaciong Z, Placha G. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study. J Hum Hypertens 2005;19(9):737-43
   PubMed Web of Science ®Google Scholar
• Hauner H, Meier M, Wendland G, et al.; Study Group SA. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. Exp Clin Endocrinol Diabetes 2004;112(4):201-7
   PubMed Web of Science ®Google Scholar
• Torp-Pedersen C, Caterson I, Coutinho W, et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007;28(23):2915-23
   PubMed Web of Science ®Google Scholar
• Garcia-Morales LM, Berber A, Macias-Lara CC, et al. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2006;28(5):770-82
   PubMed Web of Science ®Google Scholar
• Godoy-Matos A, Carraro L, Vieira A, et al. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab 2005;90(3):1460-5
   PubMed Web of Science ®Google Scholar
• Berkowitz RI, Fujioka K, Daniels SR, et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 2006;145(2):81-90
   PubMed Web of Science ®Google Scholar
• Daniels SR, Long B, Crow S, et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study. Pediatrics 2007;120(1):e147-57
   PubMed Web of Science ®Google Scholar
• Bray GA, Ryan DH, Gordon D, et al. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996;4(3):263-70
   PubMedGoogle Scholar
• Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001;50(6):505-12
   PubMed Web of Science ®Google Scholar
• Hanotin C, Thomas F, Jones SP, et al. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obes Relat Metab Disord 1998;22(1):32-8
   PubMed Web of Science ®Google Scholar
• Kaukua JK, Pekkarinen TA, Rissanen AM. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. Int J Obes Relat Metab Disord 2004;28(4):600-5
   PubMed Web of Science ®Google Scholar
• Lean ME. Sibutramine – a review of clinical efficacy. Int J Obes Relat Metab Disord 1997;21(Suppl 1):S30-6; discussion 37-9
   Google Scholar
• Binkley K, Knowles SR. Sibutramine and panic attacks. Am J Psychiatry 2002;159(10):1793-4
   PubMed Web of Science ®Google Scholar
• Clark DW, Harrison-Woolrych M. Sibutramine may be associated with memory impairment. BMJ 2004;329(7478):1316
   PubMed Web of Science ®Google Scholar
• Cordeiro Q, Vallada H. Sibutramine-induced mania episode in a bipolar patient. Int J Neuropsychopharmacol 2002;5(3):283-4
   PubMed Web of Science ®Google Scholar
• Lee J, Teoh T, Lee TS. Catatonia and psychosis associated with sibutramine: a case report and pathophysiologic correlation. J Psychosom Res 2008;64(1):107-9
   PubMed Web of Science ®Google Scholar
• Taflinski T, Chojnacka J. Sibutramine-associated psychotic episode. Am J Psychiatry 2000;157(12):2057-8
   PubMed Web of Science ®Google Scholar
• Fernandez P, Peiro AM. A sibutramine-induced delusional disorder relapse. J Neuropsychiatry Clin Neurosci 2007;19(1):88-9
   PubMed Web of Science ®Google Scholar
• Goh BK, Ng PP, Giam YC. Severe bullous drug eruption due to sibutramine (Reductil). Br J Dermatol 2003;149(1):215-6
   PubMed Web of Science ®Google Scholar
• Chounta A, Tsiodras S, Zouridakis S, et al. Sibutramine use associated with reversible hepatotoxicity. Ann Intern Med 2005;143(10):763-4
   PubMed Web of Science ®Google Scholar
• Harrison-Woolrych M, Clark DW, Hill GR, et al. QT interval prolongation associated with sibutramine treatment. Br J Clin Pharmacol 2006;61(4):464-9
   PubMed Web of Science ®Google Scholar
• Bach DS, Rissanen AM, Mendel CM, et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res 1999;7(4):363-9
   PubMedGoogle Scholar
• Zannad F, Gille B, Grentzinger A, et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 2002;144(3):508-15
   PubMed Web of Science ®Google Scholar
• Faria AN, Ribeiro Filho FF, Lerario DD, et al. Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. Arq Bras Cardiol 2002;78(2):172-80
   PubMedGoogle Scholar
• Cole JO, Levin A, Beake B, et al. Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines. J Clin Psychopharmacol 1998;18(3):231-6
   PubMed Web of Science ®Google Scholar
• Schuh LM, Schuster CR, Hopper JA, Mendel CM. Abuse liability assessment of sibutramine, a novel weight control agent. Psychopharmacology (Berl) 2000;147(4):339-46
   PubMed Web of Science ®Google Scholar
• De Santis M, Straface G, Cavaliere AF, et al. Early first-trimester sibutramine exposure: pregnancy outcome and neonatal follow-up. Drug Saf 2006;29(3):255-9
   PubMed Web of Science ®Google Scholar
• Benazzi F. Organic hypomania secondary to sibutramine-citalopram interaction. J Clin Psychiatry 2002;63(2):165
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Tsouli S, Filippatos TD, et al. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. Nutr Metab Cardiovasc Dis 2008;18(3):207-10
   PubMed Web of Science ®Google Scholar
• Henderson DC, Copeland PM, Daley TB, et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005;162(5):954-62
   PubMed Web of Science ®Google Scholar
• Henderson DC, Fan X, Copeland PM, et al. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 2007;115(2):101-5
   PubMed Web of Science ®Google Scholar
• Milano W, Petrella C, Casella A, et al. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study. Adv Ther 2005;22(1):25-31
   PubMed Web of Science ®Google Scholar
• Wilfley DE, Crow SJ, Hudson JI, et al. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. Am J Psychiatry 2008;165(1):51-8
   PubMed Web of Science ®Google Scholar
• Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998;21(8):1288-94
   PubMed Web of Science ®Google Scholar
• Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352(9123):167-72
   PubMed Web of Science ®Google Scholar
• Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999;281(3):235-42
   PubMed Web of Science ®Google Scholar
• Rossner S, Sjostrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000;8(1):49-61
   PubMedGoogle Scholar
• Finer N, James WP, Kopelman PG, et al. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000;24(3):306-13
   PubMed Web of Science ®Google Scholar
• Muls E, Kolanowski J, Scheen A, Van Gaal L. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001;25(11):1713-21
   PubMed Web of Science ®Google Scholar
• Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 1999;69(6):1108-16
   PubMed Web of Science ®Google Scholar
• Chanoine JP, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005;293(23):2873-83
   PubMed Web of Science ®Google Scholar
• Richelsen B, Tonstad S, Rossner S, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care 2007;30(1):27-32
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27(1):155-61
   PubMed Web of Science ®Google Scholar
• Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000;160(9):1321-6
   PubMed Web of Science ®Google Scholar
• Padwal R, Majumdar SR, Johnson JA, et al. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005;28(3):736-44
   PubMed Web of Science ®Google Scholar
• Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002;25(6):1033-41
   PubMed Web of Science ®Google Scholar
• Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002;25(7):1123-8
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002;4(6):415-23
   PubMed Web of Science ®Google Scholar
• Berne C. A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin. Diabet Med 2005;22(5):612-8
   PubMed Web of Science ®Google Scholar
• Mannucci E, Dicembrini I, Rotella F, Rotella CM. Orlistat and sibutramine beyond weight loss. Nutr Metab Cardiovasc Dis 2008;18(5):342-8
   PubMed Web of Science ®Google Scholar
• O'Meara S, Riemsma R, Shirran L, et al. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev 2004;5(1):51-68
   PubMedGoogle Scholar
• Wirth A. Reduction of body weight and co-morbidities by orlistat: The XXL–Primary Health Care Trial. Diabetes Obes Metab 2005;7(1):21-7
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368(9548):1660-72
   PubMed Web of Science ®Google Scholar
• Hollander P. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. Am J Med 2007;120(2 Suppl 1):S18-28; discussion S29-32
   PubMed Web of Science ®Google Scholar
• Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353(20):2121-34
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365(9468):1389-97
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295(7):761-75
   PubMed Web of Science ®Google Scholar
• Hampp C, Hartzema AG, Kauf TL. Cost-utility analysis of rimonabant in the treatment of obesity. Value Health 2008;11(3):389-99
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Despres JP, Scheen A, et al. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. J Hypertens 2008;26(2):357-67
   PubMed Web of Science ®Google Scholar
• Kakafika AI, Mikhailidis DP, Karagiannis A, Athyros VG. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharmacol 2007;47(5):642-52
   PubMed Web of Science ®Google Scholar
• Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142(7):532-46
   PubMed Web of Science ®Google Scholar
• Neovius M, Johansson K, Rossner S. Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis. Obes Rev 2008 [Epub ahead of print]
   Google Scholar
• Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335(7631):1194-9
   PubMed Web of Science ®Google Scholar
• Perrio MJ, Wilton LV, Shakir SA. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity (Silver Spring) 2007;15(11):2712-22
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Lueiro M, Fernandez ML. Orlistat-induced cutaneous leukocytoclastic vasculitis. Arthritis Rheum 2002;47(5):567
   PubMed Web of Science ®Google Scholar
• Sergeant A, Milne G, Shaffrali F. Lichenoid eruption associated with orlistat. Br J Dermatol 2006;154(5):1020-1
   PubMed Web of Science ®Google Scholar
• Azar ST, Zantout MS. Diabetic ketoacidosis associated with orlistat treatment. Diabetes Care 2001;24(3):602
   PubMed Web of Science ®Google Scholar
• Montero JL, Muntane J, Fraga E, et al. Orlistat associated subacute hepatic failure. J Hepatol 2001;34(1):173
   PubMed Web of Science ®Google Scholar
• Lau G, Chan CL. Massive hepatocellular [correction of hepatocullular] necrosis: was it caused by Orlistat? Med Sci Law 2002;42(4):309-12
   PubMed Web of Science ®Google Scholar
• Umemura T, Ichijo T, Matsumoto A, Kiyosawa K. Severe hepatic injury caused by orlistat. Am J Med 2006;119(8):e7
   PubMed Web of Science ®Google Scholar
• Aronne LJ, Isoldi KK. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy. Am J Cardiol 2007;100(12A):18P-26P
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Cannon CP. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential. Am J Cardiol 2007;100(12A):27P-32P
   Google Scholar
• Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007;370(9600):1706-13
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008;299(13):1547-60
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Derdemezis CS, Gazi IF, et al. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008;31(1):53-65
   PubMed Web of Science ®Google Scholar
• Di Francesco V, Sacco T, Zamboni M, et al. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study. Ann Nutr Metab 2007;51(1):75-81
   PubMed Web of Science ®Google Scholar
• Cuellar GE, Ruiz AM, Monsalve MC, Berber A. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res 2000;8(1):71-82
   PubMedGoogle Scholar
• De Simone G, Romano C, De Caprio C, et al. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects. Nutr Metab Cardiovasc Dis 2005;15(1):24-30
   PubMed Web of Science ®Google Scholar
• Birkenfeld AL, Schroeder C, Pischon T, et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients – sibutramine and blood pressure. Clin Auton Res 2005;15(3):200-6
   PubMed Web of Science ®Google Scholar
• Onyike CU, Crum RM, Lee HB, et al. Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2003;158(12):1139-47
   PubMed Web of Science ®Google Scholar
• Dixon JB, Dixon ME, O'Brien PE. Depression in association with severe obesity: changes with weight loss. Arch Intern Med 2003;163(17):2058-65
   PubMed Web of Science ®Google Scholar